ORANGEBURG, N.Y., April 20, 2009 (GLOBE NEWSWIRE) -- IMPULSE Dynamics, manufacturer of the OPTIMIZER System for patients with heart failure, announced today that it has recently closed a new round of financing of $40MM USD from institutional and private investors that will provide the necessary capital for realizing its strategic plans.
The OPTIMIZER System, which is CE marked, is commercially available in parts of Europe and Asia and is being investigated in the United States, and delivers cardiac contractility modulating (CCM) signals that are intended to improve the strength of heart muscle contraction. IMPULSE Dynamics recently released the findings of its 428 patient one year study of the OPTIMIZER System conducted in the U.S. Heart failure is a disease that affects more than 22 million people around the world, many of which have no treatment options.
"This new financing, coupled with the recently available results of our U.S. study will provide IMPULSE Dynamics the opportunity to enhance commercial activities outside of the U.S. and form the foundation for obtaining additional data to gain approval of the OPTIMIZER System by the U.S. Food and Drug Administration," stated Dr. Yuval Mika, chief operating officer, IMPULSE Dynamics.
About IMPULSE Dynamics
IMPULSE Dynamics, with offices in U.S., Switzerland and Israel, is a pioneering medical device company focused on the development and commercialization of the OPTIMIZER System, an implantable device for the treatment of medically refractory heart failure. Additional information can be found at www.impulse-dynamics.com.
Forward-Looking Statements
This press release contains forward-looking statements about IMPULSE Dynamics, including projections about its business and the congestive heart failure market. These forward-looking statements are not guarantees of future performance and actual results could differ significantly.